Neuphoria Q1 update: BNC-210 Phase 3 topline due Q3 2025; cash runway into Q3 2026

Neuphoria Therapeutics Inc.

Cash runway extends into Q3 2026; no near-term financing risk stated.
Phase 3 AFFIRM-1 trial of BNC-210 for social anxiety disorder on track for topline readout in Q3 2025.
Partnered α7 nAChR PAM MK-1167 (Merck) in Phase 2 for Alzheimer's disease.
Phase 2b SYMPHONY trial for BNC-210 in PTSD planned after positive FDA End-of-Phase 2 meeting.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.